The Pennant Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PNTG research report →
Range $48 – $49
Price Chart
About the company
The Pennant Group, Inc. is a U. S.
- CEO
- Brent J. Guerisoli
- IPO
- 2019
- Employees
- 9,700
- HQ
- Eagle, ID, US
Get TickerSpark's AI analysis on PNTG
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.22B
- P/E
- 32.78
- Fwd P/E
- 25.02
- PEG
- 1.04
- P/S
- 1.02
- P/B
- 3.18
- EV/EBITDA
- 22.34
- Div Yield
- 0.00%
- Gross Margin
- 13.37%
- Op Margin
- 5.94%
- Net Margin
- 3.05%
- ROE
- 10.15%
- ROIC
- 5.62%
Latest fiscal year · YoY change
- Revenue
- $947.71M+36.3%
- Gross Profit
- $122.47M+30.6%
- Op Income
- $51.39M
- Net Income
- $29.58M+31.1%
- EPS
- $0.86+19.4%
- OCF Growth
- +22.9%
- FCF Growth
- -13.2%
- 52W High
- $44.24
- 52W Low
- $25.57
- 50D MA
- $39.78
- 200D MA
- $36.04
- Beta
- 1.30
- RSI (14)
- 36
- Avg Volume
- 389.91K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Pennant delivered strong Q3 growth across revenue, EBITDA, and admissions, while saying higher employee benefits costs and senior living transition friction tempered margins but did not change full-year guidance.· November 5, 2026
- Q3 revenue rose 32% to $302.3 million, adjusted EBITDA increased 42.4% to $24.7 million, and adjusted EPS was $0.35, up 16.7% year over year.
- Home health and hospice remained the growth engine: segment revenue rose 38.2% to $239.8 million, with same-store admissions up 8% and Medicare admissions up 12%.
- Senior living grew revenue 12.6% to $62.4 million, but adjusted EBITDA was only $5.7 million as two markets were hit by acquisition-related transition pressure and lower occupancy.
- Management said elevated benefits costs added about 50 basis points of revenue pressure in Q3 and expects a similar hit in Q4.
- The company reaffirmed full-year guidance and said the Amedisys/UnitedHealth integration is largely complete, with remaining disruption expected to be ordinary and temporary.
Pennant reported Q3 2026 total revenue of $302.3 million, up 32% year over year. Adjusted EBITDA was $24.7 million, up 42.4%, and adjusted EBITDA prior to NCI was $26.1 million, up 44%. GAAP diluted EPS was $0.26 and adjusted diluted EPS was $0.35, with adjusted EPS up 16.7% year over year. Home health and hospice segment revenue was $239.8 million, up $66.2 million or 38.2%, and segment adjusted EBITDA was $38.1 million, up 42%; senior living revenue was $62.4 million, up 12.6%, and adjusted EBITDA was $5.7 million, up 3%. Management said higher employee benefits costs created roughly 50 bps of revenue impact in Q3 and expects similar pressure in Q4. The company ended the quarter with $103 million outstanding on its line of credit, $18.4 million in cash, 1.95x net debt to adjusted EBITDA, and $25.1 million of cash flow from operations. On guidance, management said it is reaffirming annual guidance and expects to hit its full-year targets; it also said Q4 should reflect the expected elevated benefits expense and continued, but ordinary, transition disruption from the Southeast integration.
Brent Guerisoli framed the quarter as another step in Pennant’s multi-year growth story, emphasizing “exceptional growth, consistent execution,” and progress toward long-term objectives. He highlighted the company’s operating model, leader development, and geographic expansion, noting more than 100 CEOs-in-training this year and saying the company is building capacity for continued growth. He also acknowledged margin pressure from higher benefits costs, but said Pennant remains confident in its strategy and in its ability to achieve full-year guidance.
Lynette Walbom focused on the reported financials and liquidity. She cited $302.3 million of revenue, $24.7 million of adjusted EBITDA, $26.1 million of adjusted EBITDA prior to NCI, GAAP diluted EPS of $0.26, and adjusted diluted EPS of $0.35. She also gave balance-sheet and cash-flow metrics: $103 million on the line of credit, $18.4 million cash on hand, 1.95x net debt to adjusted EBITDA, and $25.1 million of operating cash flow. On the benefits issue, management quantified the impact at about 50 bps of revenue in Q3 and said it expects a similar impact in Q4.
Analysts pressed on the Amedisys integration, asking whether the company’s guidance framework had changed and whether there were updated revenue or EBITDA expectations. Management said the branding, leadership, and EMR transitions are complete, there is still some work left on AR and patient portal items, and the disruption was the ordinary level already built into guidance, so expectations were unchanged. Questions also focused on senior living occupancy and recovery timing; management said the issues are concentrated in two markets, tied to acquisition lift and temporary leadership bandwidth, and expects Q4 to be a step in the right direction. Analysts asked about payer behavior and whether high-quality providers are gaining more leverage; management said payers are using fraud and utilization tools more actively, but it sees a strategic opportunity as payers narrow networks toward proven providers like Pennant.
The bull case is that Pennant is still compounding quickly, with strong same-store growth in home health and hospice even while integrating major acquisitions. Management repeatedly said the Southeast transition is ahead of expectations, the senior living issues are concentrated rather than systemic, and the company believes its clinical performance and local leadership model are creating long-term upside with payers and acquisition opportunities.
The main risks raised on the call were margin pressure from elevated employee benefits costs and operational lumpiness from rapid acquisition integration, especially in senior living. Management also acknowledged that some Southeast and senior living operations are still being normalized, with ordinary disruption, lower rates in some geographies, and occupancy shortfalls that could modestly affect results through year-end.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.9%
- Shares Outstanding
- 35.13M
- Float Shares
- 33.36M
of shares held by institutions
205 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aberdeen Group PLC | 3.48M | ▲ 3.48M |
| Blackrock, Inc. | 2.96M | ▼ 3.36K |
| Van Berkom & Associates Inc. | 2.17M | ▼ 203.63K |
| Vanguard Group Inc | 2.05M | ▲ 82.07K |
| Wasatch Advisors LP | 1.80M | ▼ 69.07K |
| Turtle Creek Asset Management Inc. | 1.69M | ▼ 25.88K |
| Vanguard Capital Management LLC | 1.48M | ▼ 4.78K |
| Paradigm Capital Management Inc/Ny | 1.33M | ▼ 68.00K |
| Geode Capital Management, LLC | 947.87K | ▲ 61.09K |
| State Street Corp | 904.77K | ▲ 31.76K |
| Provident Investment Management, Inc. | 894.41K | ▼ 44.79K |
| Goldman Sachs Group Inc | 891.43K | ▲ 260.04K |
Held by 250 ETFs
Biggest fund positions in PNTG by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Steik Jason Paul | sell | 218 |
| Nov 10, 26 | SMITH BARRY M | other | 5,100 |
| Oct 23, 26 | Gochnour John J | other | 5,948 |
| Oct 23, 26 | Gochnour John J | other | 6,624 |
| Oct 23, 26 | Gochnour John J | other | 5,948 |
| Oct 15, 26 | COVEY STEPHEN M R | other | 1,900 |
| Oct 15, 26 | Morris Gregory K Sr. | other | 1,900 |
| Oct 15, 26 | Snapper Suzanne D. | other | 1,900 |
| Oct 15, 26 | SMITH BARRY M | other | 1,900 |
| Oct 15, 26 | Lamb Scott E | other | 2,400 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PNTG coverage
Recent articles, reports, and earnings notes.
No research on PNTG yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PNTG report →Pennant Group to Participate in the 2026 Stephens Annual Investment Conference
globenewswire.com · Nov 13
Pennant: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 9
The Pennant Group, Inc. (PNTG) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
What The Pennant Group (PNTG) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Pennant Reports Third Quarter 2026 Results
globenewswire.com · Nov 4
Pennant Announces Third Quarter 2026 Earnings Release and Call
globenewswire.com · Nov 3
Head-To-Head Survey: The Pennant Group (NASDAQ:PNTG) vs. biote (NASDAQ:BTMD)
defenseworld.net · Oct 22
Reviewing The Pennant Group (NASDAQ:PNTG) and Guardant Health (NASDAQ:GH)
defenseworld.net · Oct 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.